Search
- Oct 20, 2023
A deep dive into the oncology target PRMT5 with the CEO of Tango Therapeutics
Barbara Weber walks us through the science of PRMT5, shares her reaction to recent data, and describes how programs are designed differently
Also look for unique social pages for BiotechTV U.
#1. Ultragenyx's Emil Kakkis on Angelman syndrome data, rare disease treatment modalities, and more
#2. The CEO of Madrigal on the launch of Rezdiffra for NASH liver disease
#3. Sutro Biopharma's CEO on ADCs, non-cell protein synthesis, and more
#4. Verve Therapeutics' CEO on today's gene editing clinical trial pause
#5. Daphne Zohar on becoming the CEO of Seaport Therapeutics and a $100M series A